PL1796725T3 - Leczenie lub profilaktyka krwawień nieplanowych u kobiet przyjmujących lek zawierający progestogen - Google Patents

Leczenie lub profilaktyka krwawień nieplanowych u kobiet przyjmujących lek zawierający progestogen

Info

Publication number
PL1796725T3
PL1796725T3 PL04774969T PL04774969T PL1796725T3 PL 1796725 T3 PL1796725 T3 PL 1796725T3 PL 04774969 T PL04774969 T PL 04774969T PL 04774969 T PL04774969 T PL 04774969T PL 1796725 T3 PL1796725 T3 PL 1796725T3
Authority
PL
Poland
Prior art keywords
progestogen
women
bleeding
dosage unit
unscheluded
Prior art date
Application number
PL04774969T
Other languages
English (en)
Inventor
Morris Notelovitz
Bennink Herman Jan Tijmen Coelingh
Petrus Jacobus Boerrigter
Original Assignee
Pantarhei Bioscience Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pantarhei Bioscience Bv filed Critical Pantarhei Bioscience Bv
Publication of PL1796725T3 publication Critical patent/PL1796725T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/553—Renin inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL04774969T 2004-09-27 2004-09-27 Leczenie lub profilaktyka krwawień nieplanowych u kobiet przyjmujących lek zawierający progestogen PL1796725T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04774969A EP1796725B1 (en) 2004-09-27 2004-09-27 Treatment or prevention of unscheluded bleeding in women on progestogen containing medication
PCT/NL2004/000667 WO2006036054A1 (en) 2004-09-27 2004-09-27 Treatment of prevention of unscheduled bleeding in women on progestogen containing medication

Publications (1)

Publication Number Publication Date
PL1796725T3 true PL1796725T3 (pl) 2009-01-30

Family

ID=34958752

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04774969T PL1796725T3 (pl) 2004-09-27 2004-09-27 Leczenie lub profilaktyka krwawień nieplanowych u kobiet przyjmujących lek zawierający progestogen

Country Status (8)

Country Link
US (1) US20090197843A1 (pl)
EP (1) EP1796725B1 (pl)
AT (1) ATE401913T1 (pl)
CA (1) CA2581927C (pl)
DE (1) DE602004015343D1 (pl)
ES (1) ES2310293T3 (pl)
PL (1) PL1796725T3 (pl)
WO (1) WO2006036054A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007234917B2 (en) * 2006-04-03 2011-05-12 Novartis Ag Renin inhibitors for the treatment of hypertension
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8633178B2 (en) 2011-11-23 2014-01-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP3145489A1 (en) 2014-05-22 2017-03-29 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552394A (en) * 1994-07-22 1996-09-03 The Medical College Of Hampton Roads Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy

Also Published As

Publication number Publication date
ES2310293T3 (es) 2009-01-01
EP1796725B1 (en) 2008-07-23
ATE401913T1 (de) 2008-08-15
CA2581927A1 (en) 2006-04-06
CA2581927C (en) 2013-04-09
DE602004015343D1 (de) 2008-09-04
WO2006036054A1 (en) 2006-04-06
EP1796725A1 (en) 2007-06-20
US20090197843A1 (en) 2009-08-06

Similar Documents

Publication Publication Date Title
PL1796725T3 (pl) Leczenie lub profilaktyka krwawień nieplanowych u kobiet przyjmujących lek zawierający progestogen
MX366119B (es) Uso de un agente inhibidor de masp-2 para el tratamiento de condiciones renales mediadas por complemento dependiente de la masp-2.
WO2005002627A3 (en) Conjugated complement cascade inhibitors
EP3530288A3 (en) Methods for treating conditions associated with masp-2 dependent complement activation
MXPA02007117A (es) Composiciones para suministrar un antagonista de cortisol..
EP1186303A3 (en) Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
WO2005011586A3 (en) Treatment and preventi0n of cardiovascular events
WO2008017664A3 (en) Application of initial doses of lhrh analogues and maintenance doses of lhrh antagonists for the treatement of hormone-dependent cancers and corresponding pharmaceutical kits
WO2008028965A3 (en) Inhibitors of protein phosphatase 1, gadd34 and protein phosphatase 1/gadd34 complex, preparation and uses thereof
WO2003094921A3 (de) Verwendung von hemmern der egfr-vermittelten signaltransduktion zur behandlung von gutartiger prostatahyperplasie (bph)/prostatahypertrophie
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
MY129668A (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
MXPA06000705A (es) Combinacion de antagonista del receptor 2 de glutamato metabotropico (mglur2) e inhibidor de acetilcolinesterasa (ache) para tratar trastornos neurologicos agudos y/o cronicos.
WO2004043456A8 (en) Cholesterol absorption inhibitors for the treatment of demyelination
WO2007056324A3 (en) Combination of an angiotensin ii receptor blocker, a calcium channel blocker and another active agent
WO2004009773A3 (en) Methods and compositions for activating or inhibiting vegf-d and vegf-c
MXPA02003484A (es) Combinaciones sinteticas de un antagonista de receptor de nk1 y un analogo estructural de gaba.
SG160323A1 (en) Methods for controlling angiogenesis and cell proliferation
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
WO2003097086A3 (en) Egf receptor antagonists in the treatment of gastric cancer
WO2001055176A3 (en) Methods for inhibiting smooth muscle cell proliferation
WO2008060535A3 (en) Use of reversine and analogs for treatment of cancer
WO2004078180A3 (en) Naaladase inhibitors for treating opioid tolerance
WO2007044325A3 (en) Apoe4 domain interaction inhibitors and methods of use thereof
WO2001044270A3 (en) Methods for treating and preventing diabetic complications by use of angiotensin-related peptides